MedTrace Logo

Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

NCT00006101 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2018-05-14

Study results available
· View outcomes & findings →

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of eflornithine (DMFO) may be an effective way to prevent the development of prostate cancer.

PURPOSE: Randomized phase II trial to determine the effectiveness of eflornithine in preventing prostate cancer in patients who are at high risk of developing the disease.

Conditions

Interventions

DRUG

eflornithine

Take 500mg of DFMO per day for 12 months

DRUG

Placebo

Take placebo per day for 12 months

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Thomas E. Ahlering

    lead OTHER

Principal Investigators

  • Thomas Ahlering, MD · Professor

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-10-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006101 on ClinicalTrials.gov